-
11m 44sPart 2 | Session 2 STRIDE: Semaglutide for Functional Capacity in Patients with T2D and PAD
-
12m 9sPart 2 | Session 3 API-CAT: Reduced Vs Full Dose Apixaban for Cancer-Associated Thrombosis
-
14m 1sPart 2 | Session 4 FRESH-UP: Liberal Intake Vs Fluid Restriction in Chronic Heart Failure
-
20m 59sPart 2 | Session 5 SOUL: Semaglutide in Patients with T2D
-
13m 47sPart 2 | Session 6 BHF PROTECT-TAVI: Cerebral Embolic Protection in TAVI
-
4m 15sPart 3 | Session 1 The Phase 3 REVERSE-IT Trial
-
4m 3sPart 3 | Session 2 EVOLUT Low Risk: 5Y Outcomes After TAVR or SAVR in Low-Risk Patients with AS
-
4m 14sPart 3 | Session 3 SMART-CHOICE 3: Clopidogrel vs Aspirin Monotherapy in High-Risk PCI Patients
-
9m 39s
-
2m 54s
-
4m 58sPart 3 | Session 6 MIGHTy-Heart: Mobile Integrated Health in Heart Failure
-
7m 33s
-
2m 46s
-
6m 34s
-
2m 46sPart 3 | Session 10 Lifetime Benefit by Control of Modifiable Risk Factors
-
10m 27sPart 3 | Session 11 CardiAMP-HF: Autologous Cell Therapy in Patients With HFrEF
-
3mPart 4 | Session 1 4 Trials That Will Change My Practice with Dr Ambarish Pandey
-
4m 27sPart 4 | Session 2 4 Trials That Will Change My Practice with Dr Dipti Itchhaporia
-
30m 45sPart 1 | Session 1 View from the Thoraxcenter: What's Hot at ACC.25?
-
39m 2sPart 1 | Session 2 View from the Thoraxcenter: ACC 25 Wrap-Up
ACC 25 - ADVANCE-HTN shows lorundrostat, an aldosterone synthase inhibitor, effectively lowered 24-hour blood pressure in patients with uncontrolled and true resistant hypertension.
Late-breaker discussion host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Luke Laffin (Cleveland Clinic, Cleveland, OH, US) to discuss the key findings from the ADVANCE-HTN trial investigating the efficacy and safety of lorundrostat in controlling blood pressure for hypertensive patients. Other key outcomes of interest include reductions in systolic and diastolic blood pressure, as well as the tolerability of the drug.
Findings showed that lorundrostat effectively lowered 24 hour blood pressure in patients with well treated uncontrolled and resistant hypertension. A dose escalation strategy from 50 to 100mg did not lower blood pressure more than 50mg, and was associated with higher rates of adverse events.
Recorded Onsite at ACC 25, Chicago.
Editors: Yazmin Sadik, Jordan Rance
Videographers: Oliver Miles
Support: This is an independent interview produced by Radcliffe CVRM.
Keep up-to-date with our video collection on the American College of Cardiology's 74th annual congress, covering late-breaking science, featured science and clinical horizon sessions. Don't miss the preview and wrap-up of the congress in our View From the Thoraxcenter series, concise Expert Interviews with select faculty offering take-home messages for practice, and our Highlights summarising the most influential trials.
More from this programme
Faculty Biographies
Harriette Van Spall
Associate Professor of Medicine, Director of E-Health and Virtual Care
Dr Harriette Van Spall is an Associate Professor of Medicine and cardiologist and serves as Director of E-Health at McMaster University, Canada. She completed her medical and postgraduate clinical training at the University of Toronto and earned a Master of Public Health degree at Harvard University, US. Dr Van Spall is a Canadian Institutes of Health Research-funded clinical trialist and researcher with a focus on heart failure, health services, and health disparities.
She has garnered more than $4 million in research funding, has won several research awards, and has published her work in high-impact medical journals. She is an invited speaker, media correspondent, and editorial board member active in peer review at several high-impact medications journals and grant funding agencies, including Canadian Institutes of Health Research and Heart and Stroke Foundation of Canada.
Dr Van Spall is an Editorial Board…
Comments